Earnings Season| INTC cash flow down, JNJ&ABBV sales show decline
1.$Intel(INTC)$ INTC Cash flow with FY22 completed
Cash flow from Operations down to ~$15 B (-48%)
Capex ~$25B (+25%)
Free Cash flow at negative ~$9.5 B
Intel has previously guided for no FCF for 2023/2024
Dividend weighs $6.0 B /yearFrom yesterday´s call on dividend
Meanwhile, there is a $0.5B difference in "other assets and liabilities" in Operating Cash flow for FY21 between yesterday´s press release the 10-K
anyone know why?On$INTC dividend question here is the reply (unfortunately I cut the reply):
2.With JNJ$Johnson & Johnson(JNJ)$ reporting we got Imbruvica sales
Imbruvica sales are shared with ABBV
4Q Imbruvica JNJ sales show a similar decline to 3Q
So ABBV$AbbVie(ABBV)$ Imbruvica FY22 impact, likely -$1 B vs FY21
FY21 sales $5.4 B ABBV Imbruvica FY22 sales guidance
4Q21 $5.4 B
2Q22 $4.7 BWe already know what to expect for EPS
Expected that Immunology will cover for Oncology
ABBV provided a Q4/FY22 guidance range update
Expected FY22 adjusted diluted EPS:
$13.70 to $13.74 (-$0.14 vs Q3 guidance of $13.84 to $13.88)
This update is due to the IPR&D and milestones charges which the company does not forecast
https://twitter.com/DividendWave/status/1618886036050026497?cxt=HHwWgoDR6biRuPcsAAAA
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
K